OPKO Health, Inc.

Equities

OPK

US68375N1037

Healthcare Facilities & Services

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-09 pm EDT			5-day change	1st Jan Change
1.26 ^USD	+0.80%		-3.08%	-16.56%

May. 07	Earnings Flash (OPK) OPKO HEALTH Posts Q1 Revenue $173.7M, vs. Street Est of $183M	MT
May. 07	Transcript : OPKO Health, Inc., Q1 2024 Earnings Call, May 07, 2024

Opko Health, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021

July 29, 2021 at 04:14 pm EDT

OPKO Health, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced total revenue was USD 442.408 million compared to USD 301.207 million a year ago. Operating income was USD 5.571 million compared to USD 27.179 million a year ago. Net loss was USD 16.186 million compared to net income of USD 33.703 million a year ago. Basic loss per share from continuing operations was USD 0.03 compared to basic earnings per share from continuing operations of USD 0.05 a year ago. For the half year, total revenue was USD 987.573 million compared to USD 512.674 million a year ago. Operating income was USD 44.008 million compared to operating loss of USD 13.581 million a year ago. Net income was USD 14.892 million compared to net loss of USD 25.429 million a year ago. Basic earnings per share from continuing operations was USD 0.02 compared to basic loss per share from continuing operations of USD 0.04 a year ago.

Latest news about OPKO Health, Inc.

Earnings Flash (OPK) OPKO HEALTH Posts Q1 Revenue $173.7M, vs. Street Est of $183M	May. 07	MT
Transcript : OPKO Health, Inc., Q1 2024 Earnings Call, May 07, 2024	May. 07
OPKO Health, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Laboratory Corp of America to Acquire BioReference's Diagnostics Business Select Assets	Mar. 28	MT
Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome	Mar. 20	CI
Opko Health Insider Bought Shares Worth $444,300, According to a Recent SEC Filing	Mar. 14	MT
Opko Health Insider Bought Shares Worth $463,750, According to a Recent SEC Filing	Mar. 13	MT
Opko Health Insider Bought Shares Worth $559,380, According to a Recent SEC Filing	Mar. 12	MT
Barrington Cuts Price Target on OPKO Health to $1.50 From $2, Maintains Outperform Rating	Feb. 28	MT
Transcript : OPKO Health, Inc., Q4 2023 Earnings Call, Feb 27, 2024	Feb. 27
Earnings Flash (OPK) OPKO HEALTH Reports Q4 Revenue $181.9M, vs. Street Est of $177.5M	Feb. 27	MT
OPKO Health, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27	CI
Drugmakers deepen efforts to tap into booming market for obesity drugs	Feb. 27	RE
Opko Health Insider Bought Shares Worth $991,700, According to a Recent SEC Filing	Feb. 21	MT
HealthSnap, Inc. announced that it has received $24.999999 million in funding from a group of investors	Feb. 20	CI
OPKO Health, Inc. Announces the Cessation of Alexis Borisy as Member of the Board of Directors and Member of Compensation Committee of the Board	Feb. 09	CI
NextPlat Preparing to Launch Opko Health Store on Alibaba's Tmall Global Platform	Feb. 05	MT
Opko Health Insider Bought Shares Worth $488,650, According to a Recent SEC Filing	Jan. 19	MT
Opko Health Insider Bought Shares Worth $386,200, According to a Recent SEC Filing	Jan. 18	MT
Opko Health Insider Bought Shares Worth $954,300, According to a Recent SEC Filing	Jan. 16	MT
Opko Health Insider Bought Shares Worth $480,379, According to a Recent SEC Filing	Jan. 11	MT
Transcript : OPKO Health, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03:45 PM	Jan. 10
OPKO Health Closes Private Offering of $230 Million Convertible Notes Due 2029	Jan. 09	MT
Opko Health Insider Bought Shares Worth $1,344,600, According to a Recent SEC Filing	Jan. 08	MT
Opko Health Insider Bought Shares Worth $514,093, According to a Recent SEC Filing	Jan. 05	MT

Chart OPKO Health, Inc.

Duration

Period

More charts

Company Profile

OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company's diagnostics segment consists of the clinical laboratory operations of BioReference Health, LLC (BioReference), its point-of-care operations. Its pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. Through BioReference, it operates specialized laboratory divisions, such as GenPath (Urology), GenPath (Oncology), and GenPath (Women's Health). It has two commercial stage pharmaceutical products and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Rayaldee, Rayaldee, Oxyntomodulin, Biologics, NGENLA Somatrogon, and Factor VIIa-CTP. It develops and manufactures specialty active pharmaceutical ingredients (APIs) through FineTech Pharmaceutical, Ltd.

Sector

Healthcare Facilities & Services

Calendar

2024-07-31 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for OPKO Health, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.25 USD

Average target price

4.25 USD

Spread / Average Target

+240.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
OPKO HEALTH, INC.	-16.56%	871M
SONIC HEALTHCARE LIMITED	-17.08%	8.39B
RADNET, INC.	+54.07%	3.74B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-37.54%	2.55B
SYNLAB AG	-9.63%	2.48B
DR. LAL PATHLABS LIMITED	-13.43%	2.32B
NEOGENOMICS, INC.	-4.20%	1.93B
FLEURY S.A.	-18.24%	1.6B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-36.41%	1.28B
METROPOLIS HEALTHCARE LIMITED	+2.19%	1.08B

Medical & Diagnostic Laboratories